Parulian Simanjuntak - Merck Tbk Independent Commissioner
| MERK Stock | IDR 3,430 10.00 0.29% |
Executive
Mr. Parulian Simanjuntak serves as Independent Commissioner of PT Merck Tbk since 2003. He is Chairman of the Audit Committee of the Company since May 2008. He obtained a degree in Business Administration from Cologne, Germany. His career started at Schering AG in Berlin, Germany. He then joined PT Schering Indonesia and served in several strategic positions, including as Finance and Administration Manager, Director of Finance, Vice President Director and finally as President Director . Currently, he dedicates himself to the International Pharmaceutical Manufacturers Group, an association of RDbased pharmaceutical companies operating in Indonesia, as its Executive Director. since 2003.
| Age | 73 |
| Tenure | 21 years |
| Phone | 62 21 2856 5600 |
| Web | https://www.merckgroup.com/id-id |
Merck Tbk Management Efficiency
The company has return on total asset (ROA) of 0.1573 % which means that it generated a profit of $0.1573 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2334 %, meaning that it generated $0.2334 on every $100 dollars invested by stockholders. Merck Tbk's management efficiency ratios could be used to measure how well Merck Tbk manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | EXECUTIVE Age | ||
| Jopy Rusli | Lippo Karawaci Tbk | 59 | |
Management Performance
| Return On Equity | 0.23 | |||
| Return On Asset | 0.16 |
Merck Tbk Leadership Team
Elected by the shareholders, the Merck Tbk's board of directors comprises two types of representatives: Merck Tbk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck Tbk's management team and ensure that shareholders' interests are well served. Merck Tbk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck Tbk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arryo Wachjuwidajat, Independent Director, Plant Director | ||
| Melisa Sandrianti, Corporate Secretary | ||
| Parulian Simanjuntak, Independent Commissioner | ||
| Aquira Moeladi, Human Head | ||
| Pachita Ramadhani, Head Mang | ||
| Bambang Nurcahyo, Finance Director | ||
| Rinita Daniati, Head Legal | ||
| Mei Tang, President Commissioner | ||
| Eduan Tjong, Supply Mang | ||
| Martin Feulner, President Director | ||
| Miranda Andamsari, Compliance Officer | ||
| Eza Evariza, Accounting Mang | ||
| Evie Yulin, Biopharma Director |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck Tbk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 2.02 T | |||
| Shares Outstanding | 448 M | |||
| Shares Owned By Insiders | 86.65 % | |||
| Shares Owned By Institutions | 2.18 % | |||
| Price To Earning | 17.23 X | |||
| Price To Book | 2.91 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Merck Stock
Merck Tbk financial ratios help investors to determine whether Merck Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Merck with respect to the benefits of owning Merck Tbk security.